at Zacks.com (Jan 15, 2015)
Citi lowers its price target on Auxilium Pharmaceuticals (AUXL -6.6%) to $22 from $27 saying expectations on revenue from the firm's Xiaflex are too high. Earlier the firm issued its own downward guidance on FY11 revenue derived from the drug to a range of $45M-$50M from $50M-$60M.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Dec 26, 2014)
at Zacks.com (Dec 24, 2014)
at Zacks.com (Dec 23, 2014)
at Zacks.com (Dec 16, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs